Federal Circuit dismisses Amgen’s Neulasta appeal
California-based Amgen is barred from succeeding on its patent infringement claim against Coherus Biosciences, according to the US Court of Appeals for the Federal Circuit.
Pfizer off-patent division to merge with Mylan
Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.
Bio-Rad wins injunction against 10X Genomics
Bio-Rad, a developer of clinical diagnostic products, secured a permanent injunction against a competitor earlier this week in a long-running dispute.
Celgene settles antitrust class-action for $55m
US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.
Vaccines growth offsets Advair generic pain for GSK
Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.
Gilead licenses HIV injections for $25m
Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology.
FDA opens US to Lyrica generics
The US Food and Drug Administration last week approved nine applications for the first generic versions of Pfizer’s Lyrica.
UK High Court rules Roche patent is invalid
The English High Court has ruled that a patent owned by Roche should be revoked on grounds of insufficiency.
Sigma-Aldrich submits CRISPR petition at USPTO
Merck KGaA-owned Sigma-Aldrich has petitioned the US Patent and Trademark Office to open an interference proceeding between its own pending CRISPR-Cas9 patents and patents awarded to the University of California, Berkeley.
Endo pays $2.3m to settle states antitrust claims
Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
